Sanofi-aventis

Chinoin Gyogyszer Es Vegyeszeti Termekek Gyara Rt.

Egis Gyogyszergyar Nyilvanosan Mukodo Reszvenytarsasag

Sanofi

Kabi Pharmacia Ab

Chinoin Gyogyszer Es Vegyeszeti

Chinoin, Ltd.

Tibor Szabo

Sandor Batori

Zoltan Kapui

Peter Aranyi

Katalin Urban-Szabo

Lajos T Nagy

Edit Susan

Laszlo Balazs

Philippe Bovy

Endre Mikus

Marton Varga

Imre Bata

Gyula Dalmadi

Judit Bence

Eva Boronkay

Geza Timari

Kinga Boer

Laszlo Institoris

Karoly Kanai

Felix Hajdu

Istvan Hermecz

Gabor Kovacs

Jozsef Barkoczy

Istvan Stadler

Christophe Philippo

Maria Balogh

Balazs Volk

Laszlo Pongo

Gyula Lukacs

Judit Vargane Szeredi

Michel Finet

Zsuzsanna Tomoskozi

Erzsebet Walcz

Gyorgy Ruzsics

Maria Tothne Lauritz

Bela Koszegi

Gyula Simig

Jozsef Szejtli

Lajos Szente

Olivier Venier

Ferenc Lorant Bartha

Claudie Namane

Gyorgy Krasznai

Jozsef Ivanics

Adrienn Keszthelyi

Karoly Mozsolits

Veronika Bartane Bodor

Michel Aletru

Zoltán Kapui

Ervin Vajda

Ildiko Jodal

Gaborne Kovacs

Janos Ri

Zoltan Szeverenyi

Andras Boza

Imre Kiraly

Katalin Urban Szabo

Jozsef Debreczeni

Zsusanna Baloghnekardos

Judit Kaczmarek Nee Sebestyen

Ildiko Vidra Nee Sandor

Agnes Pappne Behr

Mihalyne Santa, Legal Representative

Resul Bahram

Marianna Kovacs

Jozsefne Ivanics

Maria Kovacs

Márton Varga

Gyuia Dalmadi

Zoltan Szevfrenyi

Jozsef Bodi

Zsuzsanna Baloghne Kardos

Sándor Batori

Péter Aranyi

Lászlo Balazs

The present invention relates to a process for the preparation of dabigatran etexilate of the formula 

Pharmaceutical intermediates and process for the preparation thereof

The present invention is related to methods for the preparation of pharmaceutically acceptable salts of (+)-7-[4-(4-fluorophenyl)-6-isopropyl-2-(methanesulfonyl-methyl-amino)-pyrimidin-5-yl]-(3R,5S,6E)-dihydroxy-hept-6-enoic acid, intermediates thereof and methods for producing said intermediates.

Method for preparing rosuvastatin salts

The present invention relates to the adenosine Areceptor ligands of the general formula (I), within them favourably to the antagonists, to their salts, solvates, N-oxides and isomers, to the pharmaceutical compositions containing the compounds of the general formula (I), their salts, solvates, N-oxides and isomers, to the use of the compounds of the general formula (I), their salts, solvates, N-oxides and isomers, to the preparation of the compounds of the general formula (I), their salts, solvates, N-oxides and isomers, as well as to the new intermediates of the general formula (II), (VI), (XI), (XII) and (XV), and to the preparation thereof.

Compounds

The present invention relates to new, potent DPP-IV enzyme inhibitors of the general formula (I), which contain fluorine atoms.

Fluoropyrrolidines having dipeptidyl peptidase enzyme inhibitory activity

The invention relates to a compound of the general formula (I), as defined herein which is useful for the treatment of a pathology in a patient wherein a CCR3 receptor plays a role in the development of the pathology, and pharmaceutical preparations containing such compound. The invention is also directed to a process for preparing the compound of the general formula (I), and intermediate useful in the preparation.

Amino-alkyl amide derivatives as CCR3 receptor ligands

The present invention relates to substituted pyrimidine compounds of formula I useful as orexin receptor antagonists. The invention also relates to pharmaceutical compositions containing said compounds. 

Pyrimidine derivatives as orexin receptor antagonists

The present invention relates to adenosine Areceptor ligands of the general formula (I), within those preferably antagonists, as well as their salts, solvates and isomers, and the pharmaceutical compositions containing them, to the use of the compounds of the general formula (I), as well as their salts, solvates and isomers, to the preparation of the compounds of the general formula (I) and their salts, solvates and isomers, furthermore to the new intermediates of the general formulae (II) and to the preparation thereof.

Triazolo-quinolin derivatives useful as adenosine receptor ligands

The present invention relates to the orexin receptor antagonists compounds of the general formula (I) as well as to their isomers, salts and solvates, to the pharmaceutical compositions containing them and to the therapeutic application thereof.

Pyrazole derivatives and use thereof as orexin receptor antagonists

The present invention relates to the novel compounds of the general formula (I) possessing dipeptidyl peptidase IV enzyme inhibitory activity, pharmaceutical compositions thereof, methods of using said compounds, processes for their preparation and intermediates of the general formulae (II), (IV), (V), (VII), (VIII) and (IX).

Compounds useful for DPP-IV enzyme inhibition

The present invention relates to adenosine A3? receptor ligands of the general formula (I), within those preferably antagonists, as well as their salts, solvates and isomers, and the pharmaceutical compositions containing them, to the use of the compounds of the general formula (I), as well as their salts, solvates and isomers, to the preparation of the compounds of the general formula (I) and theirs salts, solvates and isomers, furthermore to the new intermediates of the general formulae (II) and to the preparation thereof.

The present invention relates to a new process for the preparation of beraprost of formula (I) using new intermediates.

Process for the production of beraprost and its salts

Process for the preparation of prostaglandin E1

The invention relates to a novel process for the preparation of 13,14-dihydro-15 (R)-17-phenyl-18,19,20-trinor-PGF.sub.2.alpha. isopropyl ester of the formula (I)--wherein R stands for saturated or unsaturated straight, branched or cyclic C.sub.1-7 alkyl or phenyl or benzyl group-- ##STR1##

Process for the preparation of

Growing community of inventors

Budapest, Hungary

Tibor Szabo